Oxford BioDynamics has announced a partnership with the Goodbody Clinic to provide nationwide access to the EpiSwitch® Prostate Screening Test (PSE). The EpiSwitch PSE test, a blood test that significantly enhances the accuracy of detecting prostate cancer, will now be available at all Goodbody Clinic locations across the UK. This partnership aims to simplify the test requisitioning and sample collection process, making it more accessible to patients.

The EpiSwitch PSE test, which was launched in the UK and US in September 2023, has shown to boost the predictive accuracy of a standard PSA test from 55% to 94% when testing for the presence or absence of prostate cancer. Goodbody Clinic, a provider of private health testing services with over 140 clinics nationwide, will offer the EpiSwitch PSE test, allowing men to request the test, pay for it, and book an appointment for blood sample collection at their local clinic. Additionally, the clinic will provide a remote doctor's referral and consultation to support patients.

For those unable to visit a clinic, the Goodbody Clinic will offer the option of having a mobile nurse visit for blood sample collection. This initiative aims to provide better care and peace of mind to men throughout the country, aligning with Goodbody Clinic's commitment to accessible, high-quality healthcare.

The EpiSwitch PSE test is the result of nearly ten years of collaborative work between Oxford BioDynamics, Imperial College London, the University of East Anglia, Imperial College NHS Trust, and leading UK prostate cancer experts. It offers high accuracy, specificity, sensitivity, and predictive values to assess the risk of prostate cancer in men, as published in the peer-reviewed publication, Cancers.

This partnership marks an important milestone in extending the availability and reach of the highly accurate prostate cancer test, as stated by Thomas Guiel, Chief Operating Officer of Oxford BioDynamics. The collaboration between Oxford BioDynamics and Goodbody Clinic aims to advance the accessibility of precision medicine tests, ultimately contributing to improved healthcare outcomes for patients.